Study of GSK1203486A [MAGE-A3-ASCI] Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma.

Trial Profile

Study of GSK1203486A [MAGE-A3-ASCI] Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2014

At a glance

  • Drugs Zastumotide (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Mar 2014 Trial status changed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Jun 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top